A Phase I Dose Escalation Study of Eribulin in Combination With Weekly Carboplatin for the Treatment of Metastatic Breast Cancer
Latest Information Update: 18 Jul 2022
At a glance
- Drugs Carboplatin (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 13 Jul 2022 Status changed from active, no longer recruiting to completed.
- 27 Apr 2022 Planned End Date changed from 15 Apr 2022 to 1 Jul 2022.
- 13 Dec 2021 Planned End Date changed from 1 Dec 2021 to 15 Apr 2022.